Biocytogen (HKG: 2315), a biopharmaceutical company based in China, has announced that it has been granted a patent by the United States Patent and Trademark Office (USPTO) for its independently developed RenLite fully human common light chain mouse platform.
The RenLite mice, developed utilizing Biocytogen’s proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCETM) technology, involve the in situ replacement of the entire human antibody heavy chain variable region genes and a single light chain variable region gene. This innovation enables the generation of a highly diverse array of fully human antibodies that share a common light chain, effectively preventing light-heavy chain mismatches during the assembly of bispecific antibodies. This advancement significantly reduces the complexity of the Chemistry, Manufacturing, and Controls (CMC) process. The molecular structures of these bispecific antibodies resemble those of monoclonal antibodies, exhibiting favorable physicochemical properties.
By leveraging RenLite and RenLite Knock-Out (KO) mice, Biocytogen has created a library of antibodies targeting over 200 Tumor-Associated Antigens (TAA), facilitating the rapid development of bispecific antibody and bispecific antibody-drug conjugate (ADC) therapies.- Flcube.com
